PRMT5 inhibitors

A compound having formula I

• or a pharmaceutically acceptable salt thereof, wherein
• A is O or CH2;
• R1 is halogen, NH2, OC1-6alkyl, NHCH3, CHF2, C1-6alkyl, cyclopropyl, CH2OH, or C(CH3)2OH;
• R2 is H, C1-6alkyl, CF3 or CHF2;
• R3 is H, halogen, CH3, CF3, or CHF2, and R4 is H or NHR5, or R3 and R4 together with the atom to which they are attached form a 5-membered saturated ring containing zero or one N atom, wherein the ring is unsubstituted or substituted with CH3;
• R5 is H, CH3, C2H5, CH2CH2CH3, CH(CH3)2, CH2CHF2, CH2CF3, or CH2—C3-8cycloalkyl;
• R6 is H, C1-4alkyl, or halogen;
• R7 is H, NH2, or C1-6alkyl;
• Z1 is CH or N;
• Z2 is CH or N;
• Z3 is CH or N;
• Z4 is CH or N;
• and
• Z5 is CR 3 or N.